FATE Fate Therapeutics Inc

Fate Therapeutics to Present at Upcoming September Investor Conferences

Fate Therapeutics to Present at Upcoming September Investor Conferences

SAN DIEGO, Aug. 31, 2023 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders, today announced that the Company will participate in the following upcoming investor conferences:

Citi’s 18th Annual BioPharma Conference on Thursday, September 7, 2023 in Boston, Massachusetts

  • Hosting 1x1 investor meetings only

Wells Fargo 2023 Healthcare Conference on Friday, September 8, 2023 at 9:30 AM ET in Boston, Massachusetts

  • Participating in a fireside chat and hosting 1x1 investor meetings

A live webcast, if recorded, of each presentation can be accessed under “Events & Presentations” in the Investors section of the Company’s website at . The archived webcast will be available on the Company’s website shortly after the event.

About Fate Therapeutics, Inc.

Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune disorders. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s effector cell pipeline includes multiplexed-engineered, iPSC-derived natural killer (NK) cell and T-cell product candidates, which incorporate novel synthetic controls of cell function, such as chimeric antigen receptors (CARs) to target tumor-associated antigens, and are intended to deliver multiple mechanisms of therapeutic importance to patients including in combination with well-established cancer therapies. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit .

Contact:

Christina Tartaglia

Stern Investor Relations, Inc.

212.362.1200



EN
31/08/2023

Underlying

FATEFate Therapeutics Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Fate Therapeutics Inc

 PRESS RELEASE
Free
FATE Fate Therapeuti...

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 D...

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a single dose of FT819 with less-intensive or no conditioning chemotherapy Favorable safety profile with no dose-limiting toxicities supports plan to enable same-day discharge post FT819 treatment broadening patient ...

6h / 22m 1 EN
David Nierengarten ... (+8)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Laura Chico
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
  • Yun Zhong
XNCR XENCOR INC.
NVCR NOVOCURE LTD.
MNKD MANNKIND CORP.
FATE FATE THERAPEUTICS INC
BIIB BIOGEN INC.
ARDX ARDELYX INC
WVE WAVE LIFE SCIENCES
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
ISR ISORAY
APRE APREA THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
RVMD REVOLUTION MEDICINES
ZNTL ZENTALIS PHARMACEUTICALS
TVTX TRAVERE THERAPEUTICS INC
RZLT REZOLUTE
NUVB NUVATION BIO INC (A)
NUVL NUVALENT INC
MAZE MAZE THERAPEUTICS INC
JBIO JADE BIOSCIENCES INC
10/18/25 October 18, 2025 1 EN
Wedbush Research
  • Wedbush Research
KMX CARMAX INC.
WDC WESTERN DIGITAL CORPORATION
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
FATE FATE THERAPEUTICS INC
CRM SALESFORCE.COM INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
WVE WAVE LIFE SCIENCES
AMD ADVANCED MICRO DEVICES INC.
GM GENERAL MOTORS COMPANY
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
SMCI SUPER MICRO COMPUTER
ACET INC.
RZLT ADICET BIO INC
SANA REZOLUTE
STX SANA BIOTECHNOLOGY
GFS SEAGATE TECHNOLOGY HLDGS PLC
ARTV GLOBALFOUNDRIES INC
RNAC ARTIVA BIOTHERAPEUTICS INC
CARTESIAN THERAPEUTICS INC
10/16/25 October 16, 2025 1 EN
David Nierengarten ... (+6)
  • David Nierengarten
  • Dennis Pak
  • Geoffrey Von Der Ahe
  • Martin Fan
  • Ritika Das
  • Robert Driscoll
FATE FATE THERAPEUTICS INC
ACET ADICET BIO INC
SANA SANA BIOTECHNOLOGY
ARTV ARTIVA BIOTHERAPEUTICS INC
RNAC CARTESIAN THERAPEUTICS INC
10/16/25 October 16, 2025 1 EN
 PRESS RELEASE
Free
FATE Fate Therapeuti...

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Ad...

Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025. Mr. Adawi brings to the Company more than 20 years of financial leadership experienc...

October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch